Tuberculosis (TB)

WHO monitoring of Xpert MTB/RIF roll-out

Xpert MTB/RIF is an automated, cartridge-based nucleic amplification assay for the simultaneous detection of TB and rifampicin resistance directly from sputum in under two hours. The technology is based on the GeneXpert platform and was developed as a partnership between the Foundation for Innovative New Diagnostics (FIND), Cepheid Inc. and the University of Medicine and Dentistry of New Jersey, with support from the US National Institutes of Health. WHO endorsed the technology in December 2010 and is monitoring the global roll-out of the technology to promote coordination.

New data collection website on Xpert MTB/RIF use

Early implementers of Xpert MTB/RIF are invited to share basic information on the ongoing use of their GeneXpert instruments.

Global summary statistics of procurement


Map: procurement of concessionally-priced GeneXpert instruments by country

Available map indicators:

  • whether country has ordered at least one GeneXpert instrument
  • total number of procured GeneXpert modules
  • total number of procured Xpert MTB/RIF cartridges
Plans for the procurement of concessionally-priced GeneXpert instruments and Xpert MTB/RIF cartridges, by country

Available map indicators:

  • whether country has implementer information available
  • whether country has reported any problems
Share
Email Twitter Facebook Google Delicious LinkedIn
More...
Policy statement: Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTBRIF system
Rapid implementation of the Xpert MTB/RIF diagnostic test. Technical and operational
Checklist of prerequisites to country implementation of Xpert MTB/RIF and key action points at country level [pdf 364kb]

Fact sheet: Xpert MTB/RIF test
WHO news release: WHO endorses new rapid tuberculosis test